摘要
目的探讨棕榈酸帕利哌酮注射液治疗精神分裂症患者的疗效、安全性及经济性,为临床药物遴选及合理用药提供参考。方法选取2020年1月~2023年5月到珠海市第三人民医院就诊的96例精神分裂症患者作为研究对象,根据治疗药物不同,将患者分为研究组54例和对照组42例,分别使用棕榈酸帕利哌酮注射液和利培酮口服剂型进行治疗,随访1年;于入组时、入组后第3、6、9和12个月时,采用个人和社会功能量表、临床疗效总评量表、治疗时出现的症状量表和成本-效果比,分别评价患者的社会功能、疗效、安全性和药物经济学。结果研究组的病情严重程度下降幅度较对照组大,且在第9个月时,差异有统计学意义(P<0.05);研究组的疗效总评、治疗指数和社会功能均优于对照组,且在第3、6、9和12个月时,差异均有统计学意义(均P<0.05);研究组的成本-效果比低于对照组,差异有统计学意义(P<0.05)。结论棕榈酸帕利哌酮注射液治疗精神分裂症患者的疗效和药物经济学评价均优于利培酮口服剂型。
OBJECTIVE To explore the efficacy,safety and economy of paliperidone palmitate injection in the treatment of schizophrenia and provide reference for selection as well as clinical rational use of drug.METHODS 96 patients with schizophrenia who admitted into Zhuhai Third People?s Hospital were selected and divided into research group(54 cases) and control group(42 cases) according to different treatment plans from January,2020 to May,2023.The research group was treated with Pariperidone Palmitate Injection,while the control group was given risperidone oral preparation,both groups had received a twelve-month treatment,both group had received a one-year treatment.The social function,clinical efficacy,safety and pharmacoeconomic of two group were evaluated respectively by using the personal and Social Performance Scale,clinical global impression scale,treatment emergent symptoms scale and cost-effectiveness analysis before treatment and at the 3rd,6th,9th,12th month after treatment.RESULTS The severity of illness in the research group decreased more than control group,and the difference was statistically significant at the 9th month(P<0.05).The Global improvement,efficacy index and social function of the research group were better than those of the control group,and the difference was statistically significant at the 3rd,6th,9th,12th months(all P<0.05).The cost-effectiveness ratio of the study group was significantly lower than the control group(P<0.05).CONCLUSION The efficacy and economic value of paliperidone palmitate injection are better than risperidone.
作者
郑维思
陈芮晶
林静宜
温预关
ZHENG Weisi;CHEN Ruijing;LIN Jingyi;WEN Yuguan(Medical Teaching Department,Zhuhai Third People's Hospital,The Center of Chronic Disease Control in Zhuhai,Zhuhai,Guangdong 519000,China;Psychiatry Department,Zhuhai Third People's Hospital,The Center of Chronic Disease Control in Zhuhai,Zhuhai,Guangdong 519000,China;The Affiliated Brain Hospital of Guangzhou Medical University,Guangdong Engineering Technology Research Center for Translational Medicine of Mental Disorders,Guangzhou,Guangdong 510370,China)
出处
《今日药学》
CAS
2023年第12期928-932,共5页
Pharmacy Today
基金
珠海市医疗卫生科技计划项目(珠科创函[2020]86号)
广东省医院药学研究基金项目(2022A22)
广东省临床用药研究基金项目(2022JZ34)。